The recent price decline of 11% in Pyxis Oncology, Inc.'s (NASDAQ:PYXS) stock may have disappointed insiders who bought US$174.4k worth of shares at an average price of US$1.96 in the past 12 months.

Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Leerink Partnrs issued their FY2029 earnings estimates for shares of Pyxis Oncology in a research note issued to investors on Friday, May ...

Pyxis Advisory Group Launches in Europe Rapid growth and demand across Europe, Africa and Middle East calls for Texas-based firm to expand presence in Switzerland.

Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – William Blair issued their FY2027 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, March 18th ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20% ...

Pyxis Tankers Inc. announces share repurchase completion and chartering updates for its eco-friendly tanker and bulk vessel fleet.

The Blackmagic Pyxis 6K is a versatile and affordable modular box-style video camera with a quality full-frame sensor, perfect for filmmakers.

Shares of Pyxis Oncology plummeted 46% after Phase 1 results for PYX-201, prompting a downgrade by William Blair.

Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer.

Pyxis Oncology shares dropped 40% after phase 1 data on PYX-201 for solid tumors, as one participant death raises concern. Read more here.

Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results.